
zzso zzso designed from zzso principles are evaluated in the form of targeted zzso zzso with the aim to ultimately better control the growth of zzso zzso We compare the zzso efficacy of zzso zzso zzso zzso zzso zzso to the zzso form of an zzso approved zzso zzso of zzso zzso The zzso zzso is chosen due to its abundance in human breast zzso and its connection to low zzso On a subcutaneous zzso zzso zzso model, superior control of tumor growth is demonstrated by targeted zzso zzso relative to targeted zzso zzso zzso zzso zzso decrease in tumor volume after 32 days upon initiation of zzso Superior tumor control is also confirmed on zzso subcutaneous zzso of lower zzso zzso The zzso form of zzso zzso zzso zzso results also in better tumor control relative to the zzso zzso zzso zzso zzso zzso increase in tumor zzso Studies in zzso zzso zzso suggest that the observed efficacy could be attributed to release of zzso directly into the zzso tumor zzso from zzso zzso zzso into the tumor but not zzso by cancer zzso zzso zzso carriers engineered from zzso zzso that zzso zzso with lowering zzso form zzso defective zzso boundaries resulting in fast release of zzso zzso Our studies show that zzso zzso release zzso zzso zzso and zzso and may improve tumor control at the same or even lower administered doses relative to zzso approved zzso zzso 

